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Modeling the cost–benefit of nerve conduction studies in pre-employment
screening for carpal tunnel syndrome
by Bradley Evanoff, MD, MPH,1 Steve Kymes, PhD 1
Evanoff B, Kymes S. Modeling the cost–benefit of nerve conduction studies in pre-employment screening for
carpal tunnel syndrome. Scand J Work Environ Health. 2010;36(4):299–304.

Objective The aim of this study was to evaluate the costs associated with pre-employment nerve conduction
testing as a screening tool for carpal tunnel syndrome (CTS) in the workplace.

Methods We used a Markov decision analysis model to compare the costs associated with a strategy of screening all prospective employees for CTS and not hiring those with abnormal nerve conduction, versus a strategy
of not screening for CTS. The variables included in our model included employee turnover rate, the incidence of
CTS, the prevalence of median nerve conduction abnormalities, the relative risk of developing CTS conferred by
abnormal nerve conduction screening, the costs of pre-employment screening, and the worker’s compensation
costs to the employer for each case of CTS.

Results In our base case, total employer costs for CTS from the perspective of the employer (cost of screening
plus costs for workers’ compensation associated with CTS) were higher when screening was used. Median costs
per employee position over five years were US$503 for the screening strategy versus US$200 for a no-screening
strategy. A sensitivity analysis showed that a strategy of screening was cost-beneficial from the perspective of
the employer only under a few circumstances. Using Monte Carlo simulation varying all parameters, we found
a 30% probability that screening would be cost-beneficial.

Conclusions A strategy of pre-employment screening for CTS should be carefully evaluated for yield and
social consequences before being implemented. Our model suggests such screening is not appropriate for most
employers.

Key terms cost–benefit analysis; CTS; economic evaluation; electrodiagnostic study; musculoskeletal disorder;
MSD; post-offer pre-placement screening.

The yield and cost–benefit of pre-employment screening
strategies for occupational diseases are rarely subjected
to formal analysis (1). We developed a dynamic decision analytic model to estimate the cost–benefit of preemployment nerve conduction testing as a screening tool
for carpal tunnel syndrome (CTS) in the workplace. CTS
is a major health concern in certain occupations, resulting in frequent time away from work and high workers’
compensation costs (2, 3). Pre-employment screening
with electrodiagnostic studies (EDS) to assess nerve conduction has been promoted as a strategy to reduce CTS in
jobs requiring intensive hand activity. The rationale for
this practice is that workers with abnormal median nerve
conduction are at an increased risk of developing CTS,
so an employer’s overall rate of CTS can be reduced by

excluding workers with impaired nerve function from
hand-intensive jobs (4–6). Court decisions in the United
States support the practice of excluding workers from
jobs based on the results of nerve conduction testing (7).
A number of employers in the USA now routinely test
new workers with EDS and make hiring decisions based
on the results. However, this practice is controversial (8,
9), and there has been little evaluation of its diagnostic
test yield or cost–benefit outcome.
In the only formal cost–benefit evaluation of postoffer, pre-placement screening for CTS, Franzblau and
colleagues (10) evaluated the costs of such a screening
and job placement strategy. They analyzed retrospective
data from 2150 employees in a single automobile parts
manufacturer. In this company, all new employees were
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screened with EDS, but hiring decisions were not made
based on this information. Using workers’ compensation
claims data and information from the company about
the costs associated with screening, Franzblau et al
concluded that basing hiring decisions on the results of
EDS would not have been cost-beneficial, as the cost of
screening all new workers exceeded the cost of the CTS
cases that might have been avoided. Furthermore, while
workers with abnormal EDS at baseline had an increased
risk of developing CTS, the majority of them remained
asymptomatic. Most CTS cases actually occurred among
workers with normal EDS at baseline. This study used
data from a single employer, and the extent to which the
results can be applied to other populations is not known.
The aim of our study was to construct a model providing a more generalized cost–benefit estimation of
basing worker placement or hiring decisions on screening for CTS. In a hypothetical cohort of new employees, we compared the cost of screening all prospective
employees for CTS and not hiring those with abnormal
nerve conduction, versus a strategy of not screening for
CTS. Variability in the results was assessed with both
deterministic and probabilistic sensitivity analyses.

Methods
Model parameters
Baseline inputs to our model and the ranges for deterministic sensitivity analyses are shown in table 1. Values
were based on a review of the medical literature and
expert opinion. The cost per case of CTS was based
on published workers’ compensation claims data and
chosen to be representative of a total claim cost to the
employer or employer’s insurer for a case of CTS in the
USA, including direct medical and disability costs (3,
10, 11). The annual incidence of CTS in the entire working population (regardless of EDS results) was based on
reported workers’ compensation claims (3, 10, 12–16).
The prevalence of abnormal EDS and the relative risk of
developing CTS among asymptomatic individuals with

abnormal EDS were estimated from several studies in
working populations (10, 17–23), as well as from the
authors’ own unpublished data from an ongoing prospective study of CTS (data available from corresponding
author). The cost of screening was based on data from
local employers, occupational health practitioners, and
the Franzblau et al study (10). The lower range of this
cost estimate represents the lower screening cost that is
associated with some portable EDS devices; the upper
range is below the normal clinical charges for diagnostic
EDS. The annual turnover rate incorporated a wide range
of values to represent different industries and employment situations. The analysis was carried out from the
perspective of the employer, since employers incur the
costs of CTS attributed to work activities, and a screening program designed to reduce CTS in an employed
workforce would be paid for by the employer. We chose
a wide range of parameters for important inputs including turnover rate and cost of a case of CTS, to make
the model inclusive of different work settings and state
compensation systems. We arbitrarily chose a five-year
time horizon with a one-year time cycle. We modeled a
working population of 10 000 workers, with continued
hiring to replace workers who left employment. In the
base case, future costs were not discounted; however the
impact of discounting was tested in sensitivity analyses
by varying the discount rate by up to 10%.
Accounting for the impact of assumptions on model
outcomes
The validity of any decision analytic model, such as
the one we constructed, is limited by the assumptions
made regarding the model parameters. Therefore, we
evaluated our model using sensitivity analyses to determine the extent to which these assumptions affected the
outcome of the model. We conducted one- and two-way
sensitivity analyses, in which one or two variables are
taken through their entire respective ranges of potential
values. For the six model parameters listed in table 1, we
ran one-way sensitivity analyses for all model parameters individually, and two-way sensitivity analyses for
all combinations of two parameters.

Table 1. Inputs to the decision model, including the base model and the range of inputs used for sensitivity analysis. [EDS=electrodiagnostic
studies; RR=relative risk]
			
Carpal tunnel syndrome
Electrodiagnostic studies
			
			
Cost
Annual		
Cost of
			
Abnormal EDS
			
per case
incidence		
screening
(US$)			
(US$)
			
RR
Prevalence

Annual
employee
turnover
rate

Base model
Range for sensitivity analysis

0.15
0.0–0.5

300

20 000
7500–30 000

0.002
0.001–0.02

4
3–5
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0.15
0.05–0.25

150
120–250
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Markov model

new employees and (ii) workers’ compensation claims
for those who developed CTS. Our Markov model is
illustrated in figure 1. We conducted probabilistic sensitivity analysis using Monte Carlo simulations, with
10 000 iterations varying all model inputs simultaneously through their full ranges as listed in table 1. Our
decision analytic model was constructed using TreeAge
Pro 2009 (TreeAge Software, Inc, Williamsport, MA,
USA). Our analyses were guided by published principles of good practice for decision analytic modeling
in healthcare evaluations (25).

A Markov model is a mathematical method for estimating the costs and consequences of events that repeat in
a cyclical manner, with each set of iterations referred to
as a Markov cycle (24). In the context of this simulation,
each Markov cycle was considered to be one year, and
the events modeled over that year included the annual
probability that someone would develop CTS, continue
working without developing CTS, and leave work due
to reasons other than CTS. The model was constructed
as a dynamic cohort to maintain an average employee
group of 10 000 workers for the hypothetical employer
throughout the simulation period; employees who developed CTS or left employment during each cycle were
replaced. We compared a strategy of pre-employment
screening for abnormal nerve conduction among all new
employees versus a no-screening strategy. Included in
the model was the cost of screening additional workers to compensate for those rejected from employment based on their EDS result. Our outcome was the
expected incremental cost per employee position. The
costs included in the model were the cost of (i) screening

Results
Base model
The results of our base model comparing a strategy
of pre-employment screening versus no screening are
shown in table 2. The screening strategy resulted in the
rejection of 3279 workers for employment, out of a total
of 24 336 workers screened to maintain a population

Screening

Test positive
not hired

No screening

Employee
interviewed

Test negative
hired

Continues
employment

Quit/fired

Continues
employment

Develop CTS

Quit/fired

Develop CTS

Figure 1. Markov decision model for screening new hires using electrodiagnostic studies
(EDS) versus a no-screening strategy. This
illustrates the potential path taken by an
individual worker. In each year, a worker
could remain healthy and continue working,
develop carpal tunnel syndrome (CTS) and
incur workers’ compensation costs, or leave
the company due to reasons other than CTS.
After the employee developed CTS, they could
either keep working or leave the company.
Each time a worker quits, is fired, or is not
hired due to a “positive” or abnormal EDS,
new job applicants must be screened or
interviewed for employment.

Figure 1. Markov decision model for screening new hires using electrodiagnostic studies (EDS) versus a

Table 2. Results comparing a strategy of pre-employment screening for carpal tunnel syndrome (CTS) versus no screening in hiring and
no-screening
strategy.
illustrates
the for
potential
path taken by an individual worker. In each year,
maintaining
a population
of This
10 000
workers
five years.
a worker could remain healthy and continue working, develop CTS and incur
workers’
Outcome
compensation costs, or leave the company due to reasons other than CTS. After the employee
Workers
Workers
Cases of
Costs of
Cost of
considered
rejected for
CTS
all CTS cases
screening all
developed CTS, they could either keep working or leave the company. Each time a worker quits, is
for
employment
in the
treated under
new workers
employment
due to
employed
workers’
(US$)
fired, or is not hired (N)
due to a “positive”
or
abnormal
EDS,
new
job
applicants
must
be
screened
or
screening
workforce
compensation		
		
(N)
(N)
(US$)		
interviewed for employment.

Total cost of
screening plus
treatment of
CTS cases
in workforce
(US$)

Screening strategy

24 336

3279

69

1 380 000

3 652 520

5 032 520

No screening strategy

20 691

–

100

2 000 000

–

2 000 000
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of 10 000 workers over five years. The screened workers experienced 69 cases of CTS during the five-year
period among those employed, versus 100 cases in
the unscreened group. Workers’ compensation costs
of CTS were substantially lower under the screening
strategy (US$1 380 000 versus US$2 000 000). However, the cost of screening workers was substantial
(US$3 652 520) and far outweighed the cost savings
resulting from fewer cases of CTS among the screened
employees. In our base case, the expected incremental
cost under a screening program was US$303 greater per
employee position when compared to the no-screening
approach, as screening for CTS incurred more costs
than were saved by the reduction in CTS cases among
employees. Changing the discount rate had minimal
impact on these findings. We also found the screening to
be inefficient as 3279 workers were rejected for employment to avoid 31 additional cases of CTS (106 workers
rejected for employment for each case prevented in the
working population).
Sensitivity analysis
In a one-way sensitivity analysis, only one parameter
had a significant impact on the cost–benefit decision: the
incidence of CTS among the working population. When
this incidence was >0.012 (12 workers’ compensation
cases per 1000 workers per year), a strategy of screening
was favored. In a two-way sensitivity analysis, screening was favored only for combinations of the highest
incidence rates and highest costs per case of CTS. In our
probabilistic sensitivity analyses using 10 000 Monte
Carlo simulations, a strategy of no screening was less
expensive for the employer in 70% of the simulations.

Discussion
Although screening for median nerve abnormalities at
the time of job hiring is advocated and practiced as a
strategy to prevent CTS in the workplace (4–6, 26), there
has been little evaluation of this strategy in practice. The
only formal evaluation of this practice was performed
by Franzblau et al (10), who found that such screening
was not cost-beneficial for the employer they studied.
Our modeling used a wide range of possible values for
the cost of a case of CTS, the likelihood of such a case,
and the cost of screening. We found that a strategy of
post-offer, pre-placement screening for CTS was not
cost-beneficial in the majority of models tested. From
the perspective of most individual employers, screening
for CTS is unlikely to be cost-beneficial.
Although median nerve conduction abnormalities
are important criteria for the diagnosis of CTS, most
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asymptomatic people with such abnormalities remain
asymptomatic (10, 18–22). In the screening scenario we
modeled, 3279 workers were rejected for employment
over five years in order to avoid 31 cases of CTS for an
employer. Of these 3279 workers, 56 (1.7%) went on to
develop CTS. It is appropriate to ask how great a difference in the risk of future disease must exist between
persons hired and persons not hired in an effort to reduce
the burden of future disease. From a broader viewpoint,
rejecting workers for employment at one employer probably does not reduce the societal burden of CTS in the
total workforce. It is likely that rejected job applicants
will seek employment with other employers, often performing work with similar risk factors for CTS, and may
still develop CTS despite being rejected for employment
by one employer. Potential gain for employers must be
weighed against societal costs and costs to individual
workers, including discrimination and inappropriate
referral for treatment (8, 10, 27).
Our study had several limitations that may affect its
conclusions. Decision models using different assumptions will arrive at different answers. We chose estimates
of costs, prevalence of CTS, and increased risk of CTS
associated with abnormalities of nerve conduction from
a review of the relevant literature and conversations
with clinical experts. We modeled screening from the
viewpoint of the employer, since it is employers who
make decisions regarding the use of screening among
their workforce. This viewpoint does not account for
a number of relevant social costs that pertain to the
perspectives of individual workers or society at large.
There may be additional, unaccounted for costs of
screening to the employer; for example, the rejection
of an otherwise qualified job candidate due to median
nerve abnormality necessitates offering the position to a
potentially less qualified candidate with normal median
nerve conduction. Although our analysis suggests that
pre-employment screening for CTS is not cost-beneficial
to the majority of employers, our sensitivity analyses
indicate that under some circumstances (high incidence
rate of CTS and high cost per case) it could be costbeneficial for the employer.
As pointed out by de Kort & van Dijk more than a
decade ago (1), workplace screening policies are widespread, though they have rarely been subject to formal
analysis. Workplace screening policies are common in
the United States, where they are used to screen for susceptibility to conditions such as low-back pain, upperextremity musculoskeletal disorders, allergies to specific
compounds, and the ability to safely use a respirator.
Available studies of pre-employment screening indicate
that the yield of such practices is low. A study examining
over 100 000 pre-employment medical examinations in
the Netherlands found a low rate of employee rejection
(0.6%), and little relationship between job demands and
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the diagnoses that prompted rejection (28). The use of
spirometry and physical examination were found to add
little to the detection of relevant medical conditions for
clearance to use a respirator (29). Although screening
for musculoskeletal disorders is advocated as a way
to reduce workers’ compensation costs (30), existing
screening policies are rarely based on data showing
appropriate diagnostic yield or cost–benefit outcome.
In a systematic review of assessment for fitness for
work, Serra et al (31) found general confusion about the
decision-making process used to judge fitness for work
and very scarce scientific evidence based on empirical
data to support current practices.
Concluding remarks
We conclude that a strategy of post-offer screening for
CTS is not cost-beneficial to the majority of employers,
and any such screening should be carefully evaluated for
economic yield and social consequences before being
implemented. The techniques of cost–benefit analysis
are not widely used in the evaluation of occupational
health and safety policies, but should be used more
widely to guide rational practice.
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